Emcure Pharmaceuticals Expands Liver Disease Treatment with CDSCO Approval for Poviztra

Emcure Pharmaceuticals Ltd has received approval from the Central Drugs Standard Control Organisation (CDSCO) to use its co-marketed brand Poviztra for the treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (F2–F3). Poviztra contains innovator semaglutide (rDNA origin), manufactured by Novo Nordisk in Europe, and is now the first and only GLP-1 receptor agonist approved in India for this indication. The approval allows Emcure and its subsidiaries to expand access to an advanced treatment option for MASH, a progressive liver disease that is often linked to obesity, type 2 diabetes and other metabolic disorders, but frequently remains undiagnosed until its later stages. Through its subsidiary Zuventus Healthcare, the company also plans to strengthen awareness, diagnosis and treatment in the gastroenterology and hepatology segments. The approval is supported by findings from the global Phase III ESSENCE trial, where semaglutide achieved 63% resolution of steatohepatitis, 37% improvement in liver fibrosis, and one in three patients experienced both resolution of steatohepatitis and improvement in liver fibrosis. In addition to its established role in chronic weight management for individuals with obesity or overweight along with conditions such as hypertension, dyslipidemia and type 2 diabetes, this approval further broadens the therapeutic potential of semaglutide and represents an important step forward in addressing a disease with limited treatment options in India. $EMCURE Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.